1. 21 CFR Parts 312, 314, 511, and 514: New Drug, Antibiotic, and Biologic Drug Product Regulations (IND Rewrite). http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm120111.htm Published March 19, 1987. Updated August 5, 2010. Accessed July 26, 2016.
2. Federal Register, Vol. 74, No. 155, Thursday, August 13, 2009. https://www.gpo.gov/fdsys/pkg/FR-2009-08-13/pdf/E9-19005.pdf. Accessed July 26, 2016.
3. Investigational New Drug Application, Subpart I–Expanded Access to Investigational Drugs for Treatment Use. (Food and Drugs, 21 C.F.R. §312.300-312.320 (2009).
4. Mackey TK, Schoenfeld VJ. Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;14:17.
5. Caplan A, Ray A. The ethical challenges of compassionate use. JAMA. 2016;315(10):979–980.